Legal Representation
Attorney
Brian E. Turung
USPTO Deadlines 1 active 1 overdue
Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
---|---|---|---|---|---|
OPPOSITION
Notice of Publication |
NPUBE | Jun 30, 2022 | 1103 days overdue | Medium | Until Jul 30, 2022 |
Application History
40 eventsDate | Code | Type | Description |
---|---|---|---|
Jun 30, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
Jun 30, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
Dec 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Dec 13, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED |
Nov 27, 2024 | EXT4 | S | SOU EXTENSION 4 FILED |
Nov 27, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 2, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Oct 2, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Oct 2, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
Jul 15, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED |
Jul 15, 2024 | APET | A | ASSIGNED TO PETITION STAFF |
Jul 15, 2024 | PGEX | O | PETITION GRANTED - EXTENSION REQUEST FILED |
May 30, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
May 30, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
May 29, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
Nov 29, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Nov 28, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED |
Nov 28, 2023 | EXT2 | S | SOU EXTENSION 2 FILED |
Nov 28, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Jun 1, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
May 30, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
May 30, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
May 30, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Apr 19, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Nov 29, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Oct 17, 2022 | NEWN | I | NEW NOA TO ISSUE |
Jul 28, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Jul 26, 2022 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED |
May 31, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
May 31, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
May 11, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Apr 25, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Apr 22, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Apr 21, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Apr 21, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Jan 12, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Jan 12, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
Jan 12, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
Jan 10, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
Sep 11, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; dietary supplements for medical use, namely metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal extracts sold as a component ingredient of nutritional supplements and vitamins and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's disease, ulcerative colitis and irritable bowel syndrome
Additional Information
Pseudo Mark
SLEEP BIOTICS
Classification
International Classes
005